Related Experiment Video
Updated: May 13, 2026
Laparoscopic Radical Antegrade Modular Pancreatosplenectomy via Dorsal-Caudal Artery Approach for Pancreatic Neck-Body Cancer
Published on: November 18, 2022
First-line treatment for advanced pancreatic cancer
Nishi Kothari1, Muhammad Wasif Saif, Richard Kim
1H. Lee Moffitt Cancer Center, Tampa, FL 33612, USA.
Abstract:
Metastatic pancreatic cancer is a rapidly fatal disease with few therapeutic options. The authors summarize four abstracts (#148, #233, #158, #291) presented at the 2013 ASCO Gastrointestinal Cancers Symposium which were focused on novel agents for metastatic pancreatic cancer.
Insights
Novel agents show promise for treating metastatic pancreatic cancer, a deadly disease with limited options. Research presented at the 2013 ASCO Gastrointestinal Cancers Symposium highlighted these new therapeutic approaches.
Area of Science:
- Gastroenterology
- Oncology
- Pharmacology
Background:
- Metastatic pancreatic cancer has a poor prognosis.
- Current therapeutic options are limited.
- There is a critical need for novel treatment strategies.
Purpose of the Study:
- To summarize novel therapeutic agents for metastatic pancreatic cancer.
- To review findings presented at the 2013 ASCO Gastrointestinal Cancers Symposium.
Main Methods:
- Review of four selected abstracts (148, 233, 158, 291).
- Focus on novel agents targeting metastatic pancreatic cancer.
Main Results:
- Abstracts presented promising data on new agents.
- Specific details on agent efficacy and safety were discussed (as per individual abstracts).
Conclusions:
- Novel agents represent a potential advancement in treating metastatic pancreatic cancer.
- Further research and clinical trials are warranted.
